Hyperglycemia in Acute COVID-19 is Characterized by Adipose Tissue Dysfunction and Insulin Resistance

Reiterer, Moritz; Rajan, Mangala; Gómez-Banoy, Nicolás; Lau, Jennifer; Lg, Gómez-Escobar; Gilani, Athar Abbas Shah; Alvarez-Mulett, Sergio; Sholle, Evan; Chandar,; Bram, Yaron; Kl, Hoffman; Rubio‐Navarro, Alfonso; Uhl, S.; Ap, Shukla; Goyal, Parag; Br, tenOever; Alonso, LC; Re, Schwartz; Ej, Schenck; Safford, Monika M.; Lo, June C.

doi:10.1101/2021.03.21.21254072

Cited by 20 publications

(24 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, as with metabolic syndrome itself, dysfunction and inflammation in adipose tissue and the insulin resistance syndrome appear to be significantly associated with severity of disease. Acute infections result in a decrease in adiponectin expression and reduced circulating levels of adiponectin [ 72 ]. Data also show that severity of infection is accompanied by an increase in ectopic pancreatic and liver lipid as measured by MRI [ 73 , 74 ].…”

Section: Metabolic Syndrome and Host Response To Infectious Diseasementioning

confidence: 99%

The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease

Colca

Scherer

2022

Molecular Metabolism

View full text Add to dashboard Cite

Background Chronic disease appears connected to obesity. However, evidence suggests that chronic metabolic diseases are more specifically related to adipose dysfunction rather than to body weight itself. Scope of review Further study of the first generation “insulin sensitizer” pioglitazone and molecules based on its structure suggests that is possible to decouple body weight from the metabolic dysfunction that drives adverse outcomes. The growing understanding of the mechanism of action of these agents together with advances in the pathophysiology of chronic metabolic disease offers a new approach to treat chronic conditions, such as type 2 diabetes, fatty liver disease, and their common organ and vascular sequelae. Major conclusions We hypothesize that treating adipocyte dysfunction with new insulin sensitizers might significantly impact the interface of infectious disease and chronic metabolic disease.

show abstract

Section: Metabolic Syndrome and Host Response To Infectious Diseasementioning

confidence: 99%

The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease

Colca

Scherer

2022

Molecular Metabolism

View full text Add to dashboard Cite

show abstract

“…The table also attempts to highlight how COVID-19 associated mucormycosis might be different from non-COVID-19 associated Mucormycosis both in diabetics and non-diabetics. 19 , 20 , 21 , 22 …”

Section: Does Covid-19 (Sars-cov-2) Seem To Contribute To the Unprecedented Rise In Mucormycosis?mentioning

confidence: 99%

COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee)

Malhotra

Gupta

Mehrotra

et al. 2021

Journal of Oral Biology and Craniofacial Research

View full text Add to dashboard Cite

Even before the onslaught of COVID-19 pandemic could settle, the unprecedented rise in cases with COVID-19 associated mucormycosis has pushed the medical health to the fringe. Hyperglycaemia and corticosteroids appear to be the most consistent associations leading to the commonest manifestation of mucormycosis, Rhino-Orbito-Cerebral Mucormycosis. To address challenges right from categorisation and staging of the disease to the management of relentless progression, a multi-disciplinary expert committee was formed to handle the task in an evidence-based format to enforce best practices. The report of the committee on one hand attempts to succinctly present the currently available evidence while at the other also attempts to bridge the evidence-deficient gaps with the specialty-specific virtuosity of experts.

show abstract

“…Hyperglycemia associated with SARS-CoV-2 infection is multifactorial -insulin resistance, the stress response to severe illness, pancreatic beta-cell dysfunction, use of steroids for treatment. Amongst these, insulin resistance probably induced by adipose tissue dysfunction is the primary factor underlying hyperglycemia in COVID-19 [24].…”

Section: Association Between Blood Glucose and Viral Infectionmentioning

confidence: 99%

2-Deoxy-d-glucose Inhibits Replication of Novel Coronavirus (SARS-CoV-2) with Adverse Effects on Host Cell Metabolism

Malgotra¹,

Sharma²

2021

Preprint

View full text Add to dashboard Cite

The treatment of viral infections is challenging owing to the intricate structure and metabolism of the viruses. In addition, they can highjack host cellular metabolism, mutate and adapt to harsh environmental conditions. The novel coronavirus (SARS-CoV-2) displays further resilient attributes, making its eradication even more difficult. SARS-CoV-2 is an enveloped virus whose replication can be targeted by limiting the substrates available for structural incorporation. One such molecule that limits substrate availability and has received much attention lately is 2-Deoxy-d-glucose (2-DG). SARS-CoV-2 infection induces glycolysis, impairs mitochondrial function and damages the infected cells. Administration of 2-DG can inhibit increased glycolytic flux and some other metabolic processes to cause cessation of viral replication. This article provides a review of the mechanism of action and safety concerns associated with administering 2-DG in the treatment of COVID-19. The drug can have adverse effects on normal cell metabolism since it targets cells non-selectively, possibly in a dose-dependent manner. In addition, the drug has limited use in SARS-CoV-2 infection associated with stroke, hypoxic-ischemic encephalopathy, and critical illness.

show abstract

Hyperglycemia in Acute COVID-19 is Characterized by Adipose Tissue Dysfunction and Insulin Resistance

Cited by 20 publications

References 45 publications

The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease

The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease

COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee)

2-Deoxy-d-glucose Inhibits Replication of Novel Coronavirus (SARS-CoV-2) with Adverse Effects on Host Cell Metabolism

Contact Info

Product

Resources

About